Admetsys' FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in Hospital
Posted:
Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods.
Read full article here.
The UK's national research agency is backing a plan to speed up dementia testing with up to £80 million ($105.48 million) in funding, to improve diagnosis rates and cut waiting times that can exceed a year.
Read full article at Medscape…
Attendees
Sponsors and Exhibitors
Contact us